indicated in the treatment of a variety of painful
inflammatory conditions including those associated
with osteoarthritis, postoperative trauma, sports
injuries, acute musculoskeletal disorders including
tendonitis, tenosynovitis, sprains, strains and low
back pain, ear, nose and throat disorders, dental
surgery, bursitis/tendonitis, thrombophlebitis,
pharyngitis and gynaecological disorders.
Nimesulide is a nonsteroidal anti-inflammatory drug
(NSAID) of the sulfonanilide class. Its
anti-inflammatory, analgesic and antipyretic
activities have been demonstrated in several widely
used animal experimental models and in numerous
clinical trials. Nimesulide only weakly inhibits
prostaglandin synthesis and appears to exert its
effects through various mechanisms. It inhibits the
release of oxidants from activated neutrophils and
has a scavenging effect on hypochlorous acid without
affecting neutrophil function. Nimesulide also
decreases histamine release from tissue mast cells
and inhibits the production of platelet-activating
factor by human basophils. Furthermore, when added
in vitro to cultures of human articular chondrocytes,
nimesulide inhibits the release of stromelysin and
blocks metalloproteinase activity.
Active peptic ulcer disease. Moderate to severe
hepatic impairment. n patients who have previously
shown a hypersensitivity to it or nimesulide in any
of its dosage forms.
dose of Nimesulide in adults is 100 mg twice daily.